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Background: The failures of recent studies intended to prevent cerebral vasospasm have moved the focus of
research into delayed cerebral ischemia away from cerebral artery constriction towards other mechanisms. Recent
accumulating evidence has suggested that early brain injury is also involved in the development of delayed
cerebral ischemia, and that hydrogen can prevent early brain injury. Therefore, we have established a combination
therapy of intravenous hydrogen infusion and intra-cisternal magnesium sulfate infusion for the treatment of both
early brain injury and cerebral vasospasm. The present randomized controlled clinical trial is designed to investigate
the effects of this novel therapeutic strategy on the occurrence of cerebral vasospasm, delayed cerebral ischemia,
and clinical outcomes after high-grade subarachnoid hemorrhage.
Methods: This study is a randomized, double-blind, placebo-controlled design to be conducted in two hospitals. A
total of 450 patients with high-grade subarachnoid hemorrhage will be randomized to one of three arms: (i) Mg + H2
group, (ii) Mg group, and (iii) control group. Patients who are assigned to the Mg + H2 group will receive intra-cisternal
magnesium sulfate infusion (2.5 mmol/L) at 20 mL/h for 14 days and intravenous hydrogen-rich fluid infusion (200 mL)
twice a day for 14 days. Patients who are assigned to the Mg group will receive intra-cisternal magnesium sulfate
infusion (2.5 mmol/L) at 20 mL/h for 14 days and intravenous normal glucose-electrolyte solution (200 mL) without
added hydrogen twice a day for 14 days. Patients who are assigned to the control group will receive intra-cisternal
Ringer solution without magnesium sulfate at 20 mL/h for 14 days and intravenous normal glucose-electrolyte solution
(200 mL) without added hydrogen twice a day for 14 days. Primary outcome measures will be occurrence of delayed
cerebral ischemia and cerebral vasospasm. Secondary outcome measures will be modified Rankin scale score at 3, 6,
and 12 months and biochemical markers.
Discussion: The present protocol for a randomized, placebo-controlled study of intravenous hydrogen therapy with
intra-cisternal magnesium infusion is expected to establish the efficacy and safety of this therapeutic strategy.
Trial registration: UMIN-CTR: UMIN000014696
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Aneurysmal subarachnoid hemorrhage (SAH) accounts
for 5% of all strokes [1]. The mortality rate is approxi-
mately 50%, and 20% to 30% of surviving patients have
significant neurologic deficits [2,3]. In particular, high-
grade SAH, which is classified as Hunt and Kosnik
grades 4 and 5, accounts for approximately 20-40% of
patients with SAH, and its prognosis is extraordinarily
poor [4]. Delayed cerebral ischemia (DCI), a clinical
diagnosis previously proposed by Vergouwen et al., is
considered to be the most important cause of mortality
and morbidity [5]. Angiographic cerebral vasospasm
develops in approximately 70% of patients between 4
and 14 days after SAH, and the primary mechanism
underlying DCI was widely believed to be cerebral
vasospasm [1,6].
Numerous experimental and clinical studies have been
conducted to prevent and/or treat cerebral vasospasm,
and various prophylactic strategies against cerebral vaso-
spasm have been advocated [7-12]. For example, magne-
sium sulfate has been studied as one of the most
attractive therapeutic agents for decades [10-18]. Magne-
sium sulfate exhibits several beneficial effects such as
vasodilation of vessels and attenuation of neuronal
death. The mechanisms of these effects include blockage
of the voltage-dependent calcium channels, inhibition of
excitatory glutamate release, and interference with N-
methyl-D-aspartate-glutamate receptors [19]. Several
randomized controlled trials (RCTs) have been con-
ducted to investigate the effects of intravenous magne-
sium sulfate administration on outcome after SAH
[12-18]. However, these RCTs and meta-analyses showed
that magnesium sulfate did not decrease DCI or improve
the poor functional outcome after SAH [10-18].
Two main reasons for these negative results have been
identified. Firstly, intravenous magnesium sulfate infu-
sion results in only limited increases in cerebrospinal
fluid (CSF) magnesium levels, whereas serious adverse
events (such as bradycardia and hypotension) can occur
at serum magnesium levels >2 mmol/L [20]. Therefore,
these contradictory effects may be difficult to overcome
for clinical use of intravenous magnesium infusion.
Secondly, recent accumulating findings have suggested
that early brain injury (EBI) is involved mainly in the
development of DCI and causes the high mortality and
morbidity observed after SAH [21,22]. EBI is the product
of pathological mechanisms triggered in the brain during
the first 72 hours after SAH. However, the time from the
onset to initiation of intravenous magnesium administra-
tion was approximately 30–40 hours in most RCTs,
whereas more time is required to achieve significant
CSF magnesium levels after infusion [12,18,23]. This
time latency can also be considered as one of the rea-
sons for the negative results in RCTs.Previously, we studied the safety and efficacy of intra-
cisternal magnesium sulfate infusion and found that signifi-
cant increases in CSF magnesium levels can be achieved
without changes in serum levels [23-25]. However, the time
latency from infusion to achievement of significant CSF
magnesium level was also present with intra-cisternal infu-
sion, and remains unresolved [23]. Theoretically, magne-
sium can also exert effects on EBI [21,22], but we consider
that effective CSF magnesium levels are difficult to achieve
during the period of EBI development, regardless of
administration route. Therefore, other treatment strategies
against EBI are more promising.
Increasing evidence has suggested that enhanced oxida-
tive stress is involved in EBI as well as cerebral vasospasm
following SAH [26-29]. Hydrogen can selectively reduce
hydroxyl radicals and peroxynitrites, which are very strong
reactive oxygen species that react indiscriminately with
nucleic acids, lipids, and proteins, resulting in DNA frag-
mentation, lipid peroxidation, and protein inactivation
[30-38]. Previous studies have shown that hydrogen has
antioxidant, anti-apoptotic, anti-inflammatory, and cyto-
protective properties that are beneficial to the cell [30].
Hydrogen is highly diffusible and could potentially reach
subcellular compartments, such as the mitochondria and
nuclei, which are the primary sites of reactive oxygen
species generation and DNA damage [30,38]. In addition,
hydrogen has no side effects, and we previously showed
that hydrogen can be safely administered intravenously
in patients with ischemic stroke [33]. Furthermore, re-
cent experimental studies showed that hydrogen can
alleviate EBI after SAH via attenuation of neuronal
apoptosis [39-42].
These findings suggest that combination therapy using
intravenous hydrogen infusion and intra-cisternal magne-
sium sulfate infusion may be effective to treat both EBI
and delayed cerebral vasospasm. The present randomized
controlled clinical trial is intended to investigate the ef-
fects of intravenous hydrogen therapy with intra-cisternal
magnesium sulfate infusion on the occurrences of cerebral




This study is a randomized, double-blind, placebo-
controlled trial to be conducted in two hospitals (National
Defense Medical College Hospital and Mishuku Hospital)
and includes three arms: (i) intravenous hydrogen-rich
fluid infusion with intra-cisternal magnesium sulfate infu-
sion (Mg +H2 group), (ii) intra-cisternal magnesium sulfate
infusion only (Mg group), and (iii) placebo (control group).
The protocol was approved by the ethics committee of the
National Defense Medical College in May 2013 (#1126)
and was registered on UMIN-CTR (UMIN000014696).
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clinical practice guidelines. Written informed consent will
be obtained from each patient or family members before
inclusion in the study. The procedures performed during
the study are outlined in Figure 1.
Participants
All patients presenting with a diagnosis of SAH will be
checked for eligibility by the treating physician. Inclusion
criteria are: 20 to 80 years of age, aneurysm rupture, Hunt
and Kosnik grade 4 or 5, aneurysm treated by surgical clip-
ping within 72 hours after the onset, and written informed
consent from the patient or family member. Exclusion cri-
teria are: severe brain edema, heart dysfunction (New York
Heart Association Class III or IV), renal insufficiency
(calculated creatinine clearance rate of less than 30 mL/
min), Fisher grade 4 with massive intracerebral hematoma,
and rejection of randomization.
Randomization
Patients who fulfill the eligibility criteria will be assigned
to either the control group, Mg group, or Mg +H2 group
by stratified block randomization, which will be carried
out using a computer system by a statistician not related
to the project team to protect the double-blind design and
integrity of the study. Randomization will be stratified by
sex, age (20–60 years and older than 60 years), Hunt and
Kosnik grade, and Fisher group. The allocation ratio will
be 1:1:1. Patients, treating physicians, and investigators
assessing outcomes and analyzing data will be unaware of
the allocation.Figure 1 Flow diagram.Interventions
All participating patients will be treated according to
state-of-the art SAH management, comparable with re-
cent published international guidelines [43]. During
aneurysm clipping, a ventricular drainage tube will be
placed in the lateral ventricle, and a cisternal drainage
tube placed in the basal cistern. A spinal drainage tube
will be placed in the lumber spine immediately after the
clipping procedure. Fasudil hydrochloride (90 mg/day,
14 days) will be administered but not triple-H therapy. If
severe cerebral vasospasm is detected by cerebral angiog-
raphy at 7–10 days after surgery, fasudil hydrochloride (15
to 60 mg) will be administered via the proximal internal
carotid artery [44,45].
Patients who are assigned to the Mg +H2 group or the
Mg group will receive intra-cisternal magnesium sulfate
infusion [23]. Figure 2 illustrates the irrigation system.
Continuous infusion of 2.5 mmol/L magnesium sulfate in
Ringer solution will be administered at 20 mL/h for
14 days. Irrigation will be performed through the cisternal
to spinal drainage. The cisternal drainage tube and the
pressure control system at 20 cm H2O will be connected
by a T-connector for safe irrigation. The ventricular drain-
age and spinal drainage will be set at a pressure of 10 cm
H2O and 5 cm H2O, respectively, which can be adjusted
by the drainage volume. The respective drainage volumes
will be checked hourly to avoid overdrainage or elevated
intracranial pressure. CSF and serum magnesium ion con-
centrations will be measured daily until 14 days after sur-
gery, but the principal investigators of the trial will remain
unaware of the results. Patients assigned to the control
Figure 2 Irrigation system.
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solution at 20 mL/h for 14 days.
Patients who are assigned to the Mg +H2 group will
receive intravenous hydrogen-rich fluid infusion.
Hydrogen-rich fluid is produced using a non-destructive
hydrogen diffusion apparatus (Miz Co., Fujisawa, Japan;
Patent No. 4486157, Patent Gazette of Japan 2010) as re-
ported before [23,33]. Bags of glucose-electrolyte solu-
tion (Soldem 1, 200 mL/bag, Terumo, Tokyo, Japan) are
immersed, without opening or altering the bag, in a
water tank in which water is electrolyzed periodically to
produce water with hydrogen concentrations of up to
1.6 ppm. The concentration of hydrogen in the bag
reaches saturation, increasing to more than 1.0 ppm, be-
cause of diffusion through the wall of the bag. Additional
information describing this process can be found at:
http://www.e-miz.co.jp/english/technology.html#non_
destructivewebsite. Intravenous hydrogen-rich fluid
(200 mL) will be administered at 200 mL/h twice a day
(every 12 h). Patients assigned to the control group and
the Mg group will receive glucose-electrolyte solution
(Soldem 1, 200 mL) without added hydrogen at 200 mL/h
twice a day (every 12 h).
If severe brain edema, heart failure, or renal failure oc-
curs, the study intervention will be stopped immediately.
CT, CT angiography, and CT perfusion
Head computed tomography (CT) will be performed on
admission, and at 3, 7, 10, and 14 days after surgery.
Head CT angiography will be performed on admission
and at 7 days after surgery. Head CT perfusion will beperformed at 7 days after surgery. All images will be
reviewed by an experienced neuroradiologist to identify
the occurrence of DCI and cerebral vasospasm.Digital subtraction angiography
Cerebral digital subtraction angiography will be performed
on admission and at 7–10 days after surgery. Digital
subtraction angiography will be reviewed by an experi-
enced neuroradiologist to identify the occurrence of cere-
bral vasospasm.Transcranial Doppler
Transcranial Doppler imaging will be performed daily
until 14 days after surgery. The mean velocity of the
proximal middle cerebral artery (M1) will be recorded in
both hemispheres.Biochemical markers
Venous blood and CSF samples will be taken for assays
of several biochemical markers at 1, 3, 7, and 14 days
after surgery. Malondialdehyde will be assessed as an
indicator of oxidative stress [33,46]. Neuron-specific
enolase and S-100 calcium binding protein B will be
assessed as markers of neuronal and glial injuries
[21,47]. C-reactive protein will be assessed as an
inflammatory marker [21,48].Outcome measures
Primary outcome measures will be as follows.
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deficits (motor or speech deficits) that developed
after SAH, decrease in Glasgow Coma Scale of ≥2
points for >6 hours, or new cerebral infarction
not related to surgery, rebleeding, progressive
hydrocephalus, electrolyte or metabolic
disturbance, or infection [5,15].
– Occurrence of cerebral vasospasm: angiographic
vasospasm which is defined as moderate-to-severe
arterial narrowing on CT angiography and/or digital
subtraction angiography not attributable to athero-
sclerosis, catheter-induced spasm, or vessel hypopla-
sia. Transcranial Doppler vasospasm which is defined
as a mean flow velocity in the M1 of >120 cm/s [49].
Secondary outcome measures will be as follows.
– Modified Rankin scale score at 3, 6, and 12 months.
– Biochemical markers (malondialdehyde, neuron-
specific enolase, S-100 calcium binding protein B,
and C-reactive protein).
Sample size
Assuming that the incidence of DCI is 35% in the con-
trol group, 15% in the Mg group, and 5% in the Mg +H2
group, a total of 413 patients will be required (80%
power and 2-sided α = 0.05). However, assuming ap-
proximately 10% loss to follow up, 450 patients will need
to be recruited. Therefore, 150 patients must be ran-
domized to each intervention arm.
Statistical analysis
The study design accords to the ‘intention to treat’
principle. A test for overall comparison (e.g. analysis of
variance, or if the conditions for analysis of variance are
not met, a non-parametric equivalence such as the
Kruskal-Wallis test) will be employed for each outcome
across all three interventions, and if found to be signifi-
cant, pair-wise comparisons will be made. We appreciate
that many pair-wise comparisons suffer from Type I
(false-positive) error, so we will adjust for multiplicity of
comparisons by using steps such as Bonferroni and
Tukey's procedure. The statistical procedures for pair-
wise comparisons will depend on the nature of the data:
for example, for dichotomous outcomes, we will use
Fisher’s exact test or chi-square test as appropriate, and
for continuous outcomes we will use the t-test if the ob-
servations in each arm are normally distributed; or the
Mann–Whitney U-test if non-normally distributed. A
value of p < 0.05 will be considered significant.
Discussion
The present study is intended to investigate therapeutic
strategy against both EBI and cerebral vasospasm toprevent the development of DCI using combination
therapy with intravenous hydrogen infusion and intra-
cisternal magnesium sulfate infusion. Previously we used
intra-cisternal infusion of 15 mmol/L magnesium sulfate,
but 20% of patients experienced respiratory suppression
[23]. Therefore, we selected 2.5 mmol/L for the concen-
tration of magnesium sulfate solution in the present
study, because our recent experimental study showed
that intra-cisternal infusion of 2.5 mmol/L (5 mEq/L)
magnesium sulfate could prevent cerebral vasospasm
after SAH [50]. We expect the intra-cisternal infusion of
2.5 mmol/L magnesium sulfate to maintain the benefi-
cial effects and minimize side effects. In addition, the
dose regimen of hydrogen-rich fluid in the present trial
was based on our previous study, in which 38 patients
with acute ischemic stroke received intravenous infusion
of hydrogen-rich fluid, and adverse events included diar-
rhea in one patient (2.6%) and heart failure in one (2.6%)
[33]. Heart failure was considered to be due to volume
overload, so that heart dysfunction and renal insuffi-
ciency will be excluded in the present study.
The present protocol for a randomized, placebo-
controlled study of intravenous hydrogen therapy with
intra-cisternal magnesium infusion is expected to estab-
lish the efficacy and safety of this therapeutic strategy.
Trial status
The study is currently ongoing.
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